Explore chapters and articles related to this topic
Antiasthma Agents during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Chapter 11 covers antihistamine and expectorant use during pregnancy. The following relevant medications are included in Chapter 11: brompheniramine, cetirizine, chlorpheniramine, dexchlorpheniramine, diphenhydramine, hydroxyzine, loratadine, oxymetazoline, pheniramine, phenylephrine, pseudoephedrine, tripelennamine and triprolidine are generally considered safe for use during pregnancy. Some literature suggests that expectorants and mucolytics have efficacy for asthma treatment.
Tripelennamine
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Tripelennamine is an ethylenediamine-type histamine H1 antagonist. It is used to treat asthma, hay fever, urticaria, and rhinitis, and also in veterinary applications. Tripelennamine is administered by various routes, including topically. In pharmaceutical products, it may be employed as tripelennamine citrate (CAS number 6138-56-3, EC number 228-121-6, molecular formula C22H29N3O7) or as tripelennamine hydrochloride (CAS number 154-69-8, EC number 205-833-5, molecular formula C16H22CIN3) (1).
The clinical relationship between histamine-1 receptor antagonists and risk of cancer: a systematic review and meta-analysis
Published in Expert Review of Anticancer Therapy, 2023
Elham Bakhtiari, Nasrin Moazzen, Amir Amirabadi, Hamid Ahanchian
The risk of cancer was investigated in all case-control studies [10,13,16–18]. The risk of breast cancer was investigated in two studies [16,18]. Kelly et al. [16] studied the risk of breast cancer according to use of antihistamines in 11,628 women. Relative risk was estimated for regular use of antihistamines (>4 days per week for equal to or more than 4 weeks beginning equal to or more than 1 year before admission). Antihistamines studied included chlorpheniramine, doxylamine, triprolidine, brompheniramine, terfenadine, hydroxyzine, diphenhydramine, pyrllamlne, phenyttoxamine, cyproheptadlne, dexbrompheniramine, methapyrilene, astemizole, clemastine, dimethindene, antazoline, promethazlne, pyrrobutamlne, carblnoxamine, pheniramine, dimennydrtnate, tripelennamine, thenyldiamlne, loratadine, trimethobenzamide, pyribenzamine, trimeprazine, and other ones. The cancer risk was calculated according to type and duration of antihistamines. Duration were including less than 1 year, 1–4 years, 5–9 years, and equal to or more than 10 years. The risk of cancer was not associated with the type of antihistamines. In duration of more than 10 years, the risk of cancer was 0.5 (0.95% CI = (0.3–0.8)).
Gender differences in diversion among non-medical users of prescription opioids and sedatives
Published in The American Journal of Drug and Alcohol Abuse, 2020
Sadaf Arefi Milani, Shawnta L. Lloyd, Mirsada Serdarevic, Linda B. Cottler, Catherine Woodstock Striley
The Prescription Drug Abuse, Misuse, and Dependence Study was approved and monitored by the Washington University St. Louis Institutional Review Board. Written informed consent was obtained from participants, and interviews were conducted by trained interviewers. Quality control measures were implemented during the study period, including recording and reviewing of interviews. Participants were compensated $20 for their time and effort. Participants were asked about prescription and illicit drugs; however, this analysis is focused on prescription opioids and sedatives. Participants were asked if they had used prescription opioids (codeine, propoxyphene (Darvon), meperidine (Demerol), hydromorphone hydrochloride (Dilaudid), methadone, morphine, aspirin and oxycodone hydrochloride (Percodan), pentazocine/tripelennamine (Talwin, T’s & blues), fentanyl, hydrocodone, oxycodone hydrochloride (OxyContin), tramadol (Ultram), or other narcotic pain pills) and sedatives (chlordiazepoxide (Librium), secobarbital (Seconal), diazepam (Valium), alprazolam (Xanax), zolpidem (Ambien), or other tranquilizers, or sedatives, or sleeping pills).
Manifesto on united airways diseases (UAD): an Interasma (global asthma association – GAA) document
Published in Journal of Asthma, 2022
Angelica Tiotiu, Plamena Novakova, Ilaria Baiardini, Andras Bikov, Herberto Chong-Neto, Jaime Correia- de-Sousa, Alexander Emelyanov, Enrico Heffler, Guillermo Guidos Fogelbach, Krzysztof Kowal, Marina Labor, Stefan Mihaicuta, Denislava Nedeva, Sylvia Novakova, Paschalis Steiropoulos, Ignacio J. Ansotegui, Jonathan A. Bernstein, Louis-Philippe Boulet, Giorgio Walter Canonica, Lawrence Dubuske, Carlos Nunes, Juan Carlos Ivancevich, Pierachille Santus, Nelson Rosario, Tommaso Perazzo, Fulvio Braido
Antihistamines are the cornerstone of the treatment of AR. The use of the first-generation antihistamines (e.g. brompheniramine, chlorpheniramine, cyproheptadine, diphenhydramine, deschlorpheniramine, doxylamine, hydroxyzine, ketotifen, oxatomide, promethazine, tripelennamine) is considerably limited by side effects (i.e. drowsiness, dry mouth, nose, and throat, headache) (54).